The patent is for the company’s Urgent PC system and stimulation methods. It is used for the treatment of the overactive bladder (OAB) symptoms of urinary urgency, urge incontinence and frequency of urinary voids. Its a minimally invasive nonsurgical system designed to deliver retrograde access to the sacral plexus, through percutaneous electrical stimulation of the posterior tibial nerve.
The System combines a pulse generator and a lead set to transfer electrical current from the pulse generator to the posterior tibial nerve, and includes a single use feature to prevent reuse of the lead set. By preventing reuse of lead sets, the System eliminates the health risks otherwise associated with re-using the same electrodes, said the company.
David Kaysen, President and CEO, Uroplasty, said: This newly issued patent underscores our commitment to protect the unique features of the Urgent PC system. The system’s ease of use and treatment effectiveness, coupled with a minimally invasive procedure and single-use features, are seen as key positives by our many clinical users as well as patients treated for the symptoms of OAB.
